Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis

被引:34
作者
Lord, Sarah J. [1 ]
Marinovich, M. Luke [2 ]
Patterson, Jilian A. [3 ]
Wilcken, Nicholas [4 ]
Kiely, Belinda E. [1 ]
Gebski, Val [1 ]
Crossing, Sally [5 ]
Roder, David M. [6 ]
Gattellari, Melina [7 ]
Houssami, Nehmat [2 ]
机构
[1] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 2006, Australia
[2] Univ Sydney, Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia
[3] NSW Minist Hlth, Sydney, NSW, Australia
[4] Univ Sydney, Westmead Hospital, Sydney, NSW 2006, Australia
[5] Canc Voices NSW, Sydney, NSW, Australia
[6] Univ S Australia, Adelaide, SA 5001, Australia
[7] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
REGISTRY DATA; HAZARD RATES; CHEMOTHERAPY; RECURRENCE; DOCETAXEL; TAMOXIFEN; SURVIVAL; THERAPY;
D O I
10.5694/mja12.10026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To estimate the incidence of metastatic breast cancer (MBC) in Australian women with an initial diagnosis of non-metastatic breast cancer. Design, setting and participants: A population-based cohort study of all women with non-metastatic breast cancer registered on the New South Wales Central Cancer Register (CCR) in 2001 and 2002 who received care in a NSW hospital. Main outcome measures: 5-year cumulative incidence of MBC; prognostic factors for MBC. Results: MBC was recorded within 5 years in 218 of 4137 women with localised node-negative disease (5-year cumulative incidence, 5.3%; 95% CI, 4.6%-6.0%): and 455 of 2507 women with regional disease (5-year cumulative incidence, 18.1%; 95% CI, 16.7%-19.7%). The hazard rate for developing MBC was highest in the second year after the initial diagnosis of breast cancer. Determinants of increased risk of MBC were regional disease at diagnosis, age less than 50 years and living in an area of lower socio-economic status. Conclusions: Our Australian population-based estimates are valuable when communicating average MBC risks to patients and planning clinical services and trials. Women with node-negative disease have a tow risk of developing MBC, consistent with outcomes of adjuvant clinical trials. Regional disease at diagnosis remains an important prognostic factor.
引用
收藏
页码:688 / 692
页数:5
相关论文
共 24 条
[11]   Hazard rates of recurrence following diagnosis of primary breast cancer [J].
Jatoi, I ;
Tsimelzon, A ;
Weiss, H ;
Clark, GM ;
Hilsenbeck, SG .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 89 (02) :173-178
[12]   Why is breast-cancer mortality declining? [J].
Jatoi, I ;
Miller, AB .
LANCET ONCOLOGY, 2003, 4 (04) :251-254
[13]   Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 [J].
Mamounas, EP ;
Bryant, J ;
Leinbersky, B ;
Fehrenbacher, L ;
Sedlacek, SM ;
Fisher, B ;
Wickerham, DL ;
Yothers, G ;
Soran, A ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3686-3696
[14]   Adjuvant docetaxel for node-positive breast cancer [J].
Martin, M ;
Pienkowski, T ;
Mackey, J ;
Pawlicki, M ;
Guastalla, JP ;
Weaver, C ;
Tomiak, E ;
Al-Tweigeri, T ;
Chap, L ;
Juhos, E ;
Guevin, R ;
Howell, A ;
Fornander, T ;
Hainsworth, J ;
Coleman, R ;
Vinholes, J ;
Modiano, M ;
Pinter, T ;
Tang, SC ;
Colwell, B ;
Prady, C ;
Provencher, L ;
Walde, D ;
Rodriguez-Lescure, A ;
Hugh, J ;
Loret, C ;
Rupin, M ;
Blitz, S ;
Jacobs, P ;
Murawsky, M ;
Riva, A ;
Vogel, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) :2302-2313
[15]   Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors [J].
Mehnert, Anja ;
Berg, Petra ;
Henrich, Gerhard ;
Herschbach, Peter .
PSYCHO-ONCOLOGY, 2009, 18 (12) :1273-1280
[16]   RELATIONSHIP OF PATIENT AGE TO PATHOLOGICAL FEATURES OF THE TUMOR AND PROGNOSIS FOR PATIENTS WITH STAGE-I OR STAGE-II BREAST-CANCER [J].
NIXON, AJ ;
NEUBERG, D ;
HAYES, DF ;
GELMAN, R ;
CONNOLLY, JL ;
SCHNITT, S ;
ABNER, A ;
RECHT, A ;
VICINI, F ;
HARRIS, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :888-894
[17]  
Pink B, 2008, SOCIOECONOMIC INDEXE
[18]   Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial [J].
Roche, Henri ;
Fumoleau, Pierre ;
Spielmann, Marc ;
Canon, Jean-Luc ;
Delozier, Thierry ;
Serin, Daniel ;
Symann, Michel ;
Kerbrat, Pierre ;
Soulie, Patrick ;
Eichler, Francoise ;
Viens, Patrice ;
Monnier, Alain ;
Vindevoghel, Anita ;
Campone, Mario ;
Goudier, Marie-Josephe ;
Bonneterre, Jacques ;
Ferrero, Jean-Marc ;
Martin, Anne-Laure ;
Geneve, Jean ;
Asselain, Bernard .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) :5664-5671
[19]   Annual hazard rates of recurrence for breast cancer after primary therapy [J].
Saphner, T ;
Tormey, DC ;
Gray, R .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2738-2746
[20]   How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials [J].
Sateren, WB ;
Trimble, EL ;
Abrams, J ;
Brawley, O ;
Breen, N ;
Ford, L ;
McCabe, M ;
Kaplan, R ;
Smith, M ;
Ungerleider, R ;
Christian, MC .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2109-2117